PRIMARY SCLEROSING CHOLANGITIS MARKET ANALYSIS

The high costs associated with treatment can hamper the global primary sclerosing cholangitis market growth. Primary sclerosing cholangitis requires lifelong treatment and management as it is a chronic and progressive disease with no known cure. The treatment costs associated with PSC are immense as patients may require multiple medications, frequent doctor visits, diagnostic tests and some may eventually require liver transplantation. Liver transplantation is the only viable treatment option for patients with end stage liver disease due to PSC but it poses a huge financial burden. According to the data published by United Network for Organ Sharing in 2022, the average cost of liver transplantation in U.S. ranges between US$ 812,500– US$ 1,105,900. This includes costs related to pre-transplant care, surgery and post-transplant hospital stay and medications. Not only direct costs of the surgery but the lifelong immunosuppressive medication costs post-transplant can also add to the economic burden. In 2021, according to the report published by North American Transplant Coordinators Organization, lifetime drug costs post liver transplant  is US$ 630,000 in the U.S. Most PSC patients require lifelong treatment with ursodeoxycholic acid, which is also very expensive. Many patients need repeated hospitalizations, abdominal surgeries like stricturoplasties or gastrointestinal stromal tumor resections costing tens of thousands each time. Lifelong management with diagnostic tests like MRCP or liver biopsies can also add to the costs.

Market Opportunities: Strategic alliance and collaboration between companies

Strategic alliances and collaborations between companies can offer growth opportunities for global primary sclerosing cholangitis market. PSC is a rare and serious liver disease with limited treatment options available. Joint efforts between pharmaceutical firms and research institutes could help expedite the development of novel and more effective therapies. When companies pool their complementary strengths, it allows for sharing of risks and costs associated with drug research and clinical trials. This enables smaller players to take on ambitious projects that would otherwise be beyond their individual capabilities. Larger corporations also benefit from the specialized expertise and technologies that partners bring to the table. These can accelerate progress across multiple promising research pathways simultaneously. International organizations like the PSC Partners Seeking a Cure are already facilitating collaborative research. These connect patients, clinicians and scientists across borders to advance understanding of this condition. Publicly accessible repositories of clinical data and biological samples are enabling more targeted research approaches. Transnational consortiums funded by the European Commission and foundations like the American Liver Foundation are actively pursuing projects on improved diagnostics, biomarkers and therapies.